Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age (NCT05856227) | Clinical Trial Compass
CompletedPhase 3
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
United States, Bulgaria9 participantsStarted 2023-08-06
Plain-language summary
This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.
Who can participate
Age range3 Days – 3 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Informed consent from parent(s) or other legally acceptable representative (LAR) to participate in the study
* Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3 days to ≤ 3 months
* Diagnosis of documented or presumed bacterial LOS requiring administration of systemic antibiotic treatment
* Sufficient vascular access to receive study drug and to allow blood sampling at a site separate from the study drug infusion line
Key Exclusion Criteria:
* Refractory septic shock not responding to 60 minutes of vasopressor treatment within 48 hours before enrollment
* Proven ventilator-associated pneumonia
* Proven central nervous system infection (e.g., meningitis, brain abscess)
* Proven osteomyelitis, infective endocarditis, or necrotizing enterocolitis
* Impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula or other applicable formula) calculated to be less than 2/3 of normal for the applicable age group, OR urinary output \< 0.5 mL/kg/h (measured over at least 8 hours), OR requirement for dialysis
* Progressively fatal underlying disease, or life expectancy \< 30 days
* Use of systemic antibacterial therapy for longer than 72 hours within 7 days before start of study medication
* Participation in another clinical study with an investigational product within 30 days of enrollment in the current study